 |
|
|
 |
Inhibition of Disease Progression by a Novel Retinoid Antagonist in Animal Models of Arthritis
BLAKE C. BEEHLER, YONG-JIANG HEI, SIMON CHEN, JOHN A. LUPISELLA, JACEK OSTROWSKI, JOHN E. STARRETT, DAVID TORTOLANI, KENNETH M. TRAMPOSCH, and PETER R. RECZEK
ABSTRACT. Methods. BMS-189453 was tested in HIG-82 rabbit synovial fibroblasts to determine its ability to repress collagenase (matrix metalloproteinase-1, MMP-1) mRNA expression in vitro. Cells were stimulated with phorbol myristate acetate or interleukin 1ß and mRNA quantified by slot-blot analysis. In vivo, BMS-189453 was evaluated in 2 animal models of arthritis: collagen induced arthritis (CIA) in mice and streptococcal cell wall induced arthritis (SCWA) in rats. Clinical scores for arthritis were recorded weekly. At the end of each study, limbs were evaluated histologically. In CIA, these results were correlated with mRNA levels for collagenase-3 (MMP-13) and stromelysin-1 (MMP-3) as determined by Northern blot. Results. BMS-189453 reduced MMP-1 expression in HIG-82 synovial fibroblasts in culture. BMS-189453 treatment blocked the clinical progression of arthritis beyond soft tissue inflammation in the CIA model. In the SCWA model, BMS-189453 treatment resulted in significantly reduced swelling with no notable progression to joint distortion/destruction. Histological evaluation of the joints from animals in both models confirmed this result. Analysis of mRNA from the CIA paws showed that BMS-189453 prevented the overexpression of MMP-13 and MMP-3 in arthritic joints. Conclusion. Improvement in clinical and histologic variables in 2 separate animal models, along with simultaneous reduction in MMP expression in the affected joint, suggests that RAR antagonists such as BMS-189453 may be useful as agents to treat rheumatoid arthritis and for determining the role of MMP in disease progression. This is the first study to show the clinical potential of RAR antagonists in arthritis. (J Rheumatol 2003;30:355-63) Key Indexing Terms:
RETINOID ANTAGONIST
From the Departments of Biochemical Pharmacology, Cell and Molecular Biology, and Medicinal Chemistry, Bristol-Myers Squibb Pharmaceutical Research Institute, Buffalo, New York, USA. B.C. Beehler, MS, Biochemical Pharmacology, Bristol-Myers Squibb, Pennington, NJ; Y. Hei, PhD, Biochemical Pharmacology, Division of Medical Affairs, Roche Laboratories, Inc., Nutley, NJ; S. Chen, PhD, Bristol-Myers Squibb; J.A. Lupisella, MS, Cell and Molecular Biology; J. Ostrowski, PhD, Cell and Molecular Biology, Bristol-Myers Squibb, Pennington, NJ; J.E. Starrett, PhD, Medicinal Chemistry, Bristol-Myers Squibb, Wallingford, CT; D. Tortolani, BS, Medicinal Chemistry, Bristol-Myers Squibb, Pennington, NJ; K.M. Tramposch, PhD, Biochemical Pharmacology, State University of New York at Buffalo; P.R. Reczek, PhD, Department of Molecular and Cellular Biophysics, Roswell Park Cancer Institute, Buffalo, NY. Address reprint requests to B.C. Beehler, Bristol-Myers Squibb Company, Pharmaceutical Research Institute, 311 Pennington-Rocky Hill Road, Mail Stop 21-2.07, Pennington, NJ 08534. E-mail: blake.beehler@bms.com Submitted January 18, 2002; revision accepted July 30, 2002. |